BusinessGalectin Therapeutics to Present Clinical Data on Selective Non-Invasive Tests for the Development of Novel Therapies for Nonalcoholic SteatohepatitisBy Nasdaq OMXOct 7, 2016, 12:30 PM UTC
BusinessGalectin Therapeutics Announces Top-Line Data from Exploratory Phase 2a Pilot Trial (NASH-FX) with GR-MD-02 in NASH Patients with Advanced FibrosisBy Nasdaq OMXSep 27, 2016, 8:15 PM UTC
BusinessGalectin Therapeutics to Present at Rodman & Renshaw 18th Annual Global Investment ConferenceBy Nasdaq OMXAug 31, 2016, 12:00 PM UTC
BusinessGalectin Therapeutics Announces Results From 12-Week Extension of Phase 2a Psoriasis Clinical TrialBy Nasdaq OMXAug 25, 2016, 12:00 PM UTC
